Bio-Path Holdings Inc is a clinical & preclinical stage oncology focused antisense drug development company utilizing novel technology achieving systemic delivery for specific protein inhibition for any gene product that is over-expressed in disease.
Stock Price Prediction
Update at 5:00pm EST
6.297 - 6.348
6.348 - 6.383
5.572 - 5.624
5.624 - 5.659
5.76 - 5.843
5.843 - 5.898
as of: 2020-02-25 4:27:47 PM
Stoxline posted a SELL today, same as yesterday. Downward movement continues.
Price and moving averages has closed below its Short term moving average. Short term moving average is currently below mid-term; AND below long term moving averages. From the relationship between price and moving averages; we can see that: This stock is BEARISH in short-term; and BEARISH in mid-long term.BPTH has closed below the lower band by 11.4%. If price is in a downtrend band; this downward trend in price might continue. However a short term pullback inside the band is likely. Bollinger Bands are 61.3% narrower than normal. The narrow width of the bands suggests low volatility as compared to BPTH's normal range. The bands have been in this narrow range for 11 bars. This is a sign that the market may be about to initiate a new trend.
2019-11-26 Bio-Path Holdings Completes Safety Testing Study in Stage 2 of Phase 2 Trial The company announced it has completed the safety testing in the second stage of its Phase 2 clinical trial in acute myeloid leukemia. The post Bio-Path Holdings Completes Safety Testing Study in Stage 2 of Phase 2 Trial appeared first on Investing News Network .
2019-11-21 Bio-Path’s Shares Dip on IND Application Approval The FDA has approved Bio-Path's IND for its second drug candidate, but the news sent the company's shares down over 30 percent. The post Bio-Path’s Shares Dip on IND Application Approval appeared first on Investing News Network .
Growth measures the growth of both a company's revenue and net income. it tells investors how fast a company is growing.
Profitability measures a company’s ability to generate earnings as compared to its expenses and other relevant costs.
Solvency measures a company's ability to meet its long-term debts. Acceptable solvency ratios will vary from industry to industry.
Efficiency measures the strength of a company's return on invested capital. It can identify business that are better managed or not.
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither Stoxline.com nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the Stoxline.com web site, a user agrees not to redistribute the information found therein.